Board of Directors
Jean-Jacques Bienaimé Chief Executive OfficerBioMarin Pharmaceutical Inc.
Mr. Bienaimé joined BioMarin in May 2005 as Chief Executive Officer and member of the Board of Directors, bringing with him over 25 years of experience in the biotechnology and pharmaceutical industries. Under his leadership, the market capitalization of BioMarin went from around $450 million in May 2005 to over $3.5 billion in May 2008. BioMarin 2008 revenues around $300 million and is a fully integrated biopharmaceutical company with nearly 700 employees. From November 2002 to April 2005, Mr. Bienaimé served as Chairman, Chief executive officer, and President of Genencor, a biotechnology company focused on industrial bioproducts and targeted cancer biotherapeutics. Under his leadership, Genencor's revenues increased substantially to over $400 million and shareholder value increased dramatically, culminating in the sale of the company to Danisco in the spring of 2005 for an enterprise value of over $1.2 billion. From 1998 to late 2002, Mr. Bienaimé served as Chairman, Chief Executive Officer and President of Sangstat Medical Corporation, an immunology-focused biotechnology company that he guided to profitability prior to its acquisition by Genzyme Corporation. From 1992 to 1998, Mr. Bienaimé held several senior management positions at Rhone-Poulenc Rorer Pharmaceuticals (now Sanofi-Aventis), culminating in the position of Senior Vice President of Worldwide Marketing and Business Development responsible for, among other things, the launch of Lovenox® (for the prevention of pulmonary embolism and treatment of unstable angina) in the United States and Taxotere® (for breast and lung cancer) worldwide. Earlier in his career, he worked at Genentech, Inc. where he was involved in the launch of tissue plasminogen activator (t-PA) for the treatment of heart attacks.
Mr. Bienaimé is Chairman of the Board of Directors of NeurogesX, Inc., a member of the Board of Directors of Ensemble Discovery Corporation, and is a member of the Advisory Board of Bellevue Asset Management's BioVentures II fund. He received an M.B.A from the Wharton School at the University of Pennsylvania and an undergraduate degree in economics from the Ecole Superieure de Commerce de Paris.
Mr. Grey was appointed to BioMarin’s Board of Directors in December 2005. He is the former President and Chief Executive Officer of Auspex Pharmaceuticals, Inc., a privately held biotechnology company. Prior to joining Auspex, Mr. Grey acted as President and Chief Executive Officer of SGX Pharmaceuticals, a biotechnology company acquired by Eli Lilly. From 1999 to 2001, Mr. Grey acted as President, Chief Executive Officer and board member of Trega Biosciences, Inc., a biotechnology company that was acquired by Lion Bioscience AG. From November 1994 to August 1998, Mr. Grey was the President of BioChem Therapeutic, Inc., the pharmaceutical operating division of BioChem Pharma Inc., responsible for all company operations including research, development, sales and marketing, finance and human resources. Prior to this, in 1994, Mr. Grey served as President and Chief Operating Officer for Ansan, Inc. From 1974 to 1993, he served in various roles with Glaxo Inc. and Glaxo Holdings, plc, culminating in the position of Vice President, Corporate Development. Mr. Grey currently serves as a director of Achillion Pharmaceuticals, Inc. and IDM Pharma, Inc. (formerly known as Epimmune Inc.). He received a B.Sc. in chemistry from the University of Nottingham, United Kingdom.
Dr. Heron has served as a Director of BioMarin since July 2002. She is the Chairman and Chief Executive Officer of Amplyx Pharmaceuticals, Inc. Prior to December 2008, she served as Chairman and Chief Executive Officer of Labcyte Inc. (formerly Picoliter Inc.), a position she assumed in July 2001. Dr. Heron spent six years in increasingly responsible positions at the Applied Biosystems Group of Applera Corporation, including the positions of General Manager and Vice President of Sales and Marketing. From 1995 to 1996, she served as Vice President of Marketing at Affymetrix, Inc. Dr Heron earned a B.S. in chemistry with highest distinction and a Ph.D. in analytical biochemistry from Purdue University and an M.B.A. from Pepperdine University.
Pierre Lapalme Former President and Chief Executive Officer, North America Ethypharm, Inc.Mr. Lapalme has served as a Director of BioMarin since January 2004. From 1995 until his retirement in 2003, he served as the President and Chief Executive Officer of North America Ethypharm, Inc., a drug delivery company. Throughout his career, Mr. Lapalme held numerous senior management positions in the pharmaceutical industry including Chief Executive Officer and Chairman of the Board (1979-1994) of Rhône-Poulenc Pharmaceuticals, Inc. in Canada, and Senior Vice President and General Manager of North America Ethicals, a division of Rhône-Poulenc Rorer, Inc. Mr. Lapalme served on the board of the National Pharmaceutical Council and was a board member of the Pharmaceutical Manufacturers Association of Canada where he played a leading role in reinstituting patent protection for pharmaceuticals. Mr. Lapalme studied at the University of Western Ontario and INSEAD France.
V. Bryan Lawlis, Ph.D. President & Chief Executive Officer, Itero Biopharmaceuticals, Inc.Mr. Lawlis, Ph.D., currently acts as President and Chief Executive Officer of Itero Biopharmaceuticals, Inc.. Dr. Lawlis served as President and Chief Executive Officer of Aradigm Corporation from August 2004, and served on its Board of Directors from February 2005 until August 2006. Dr. Lawlis served as Aradigm Corporations's President and Chief Operating Officer from June 2003 to August 2004 and its Chief Operating Officer from November 2001 to June 2003. Previously, Dr. Lawlis founded Covance Biotechnology Services, a contract biopharmaceutical manufacturing operation, and served as its President and Chief Executive Officer from 1996 to 1999, and as Chairman from 1999 to 2001, when it was sold to Diosynth RTP, Inc., a division of Akzo Nobel, NV. From 1981 to 1996, Dr. Lawlis was employed at Genencor, Inc. and Genentech, Inc. His last position at Genentech was Vice President of Process Sciences. Dr. Lawlis holds a B.A. in microbiology from the University of Texas at Austin, and a Ph.D. in biochemistry from Washington State University.
Alan Lewis, Ph.D. Executive Chairman, Ambit BiosciencesDr. Lewis was elected to BioMarin's Board of Directors in June 2005 and has been appointed as the Board liason to the company's Scientific Advisory Board. He currently serves as Executive Chairman of Ambit Biosciences and was previously the President and Chief Executive Officer of the Juvenile Diabetes Research Foundation (JDRF). Prior to joining JDRF, Dr. Lewis served as President and CEO of Novocell Inc., a stem cell engineering company. Previously, he was the President of Celgene Signal Research and President and Chief Executive Officer of Signal Pharmaceuticals, Inc., where he guided the company to its successful acquisition by Celgene. From 1979 to 1994, Dr. Lewis held a number of positions at Wyeth-Ayerst Research and its predecessor Wyeth Laboratories, Inc., including Vice President of Research at Wyeth-Ayerst. Dr. Lewis has published over 120 full manuscripts and has written and edited seven books and 100 abstracts. Dr. Lewis was a Research Associate at Yale University from 1972 to 1973. Dr. Lewis received a B.Sc. in physiology and biochemistry from Southamptom University, Southampton, Hampshire, U.K., and a Ph.D. in pharmacology from the University of Wales, Cardiff, U.K.
Mr. Meier joined the BioMarin Board in December 2006. Mr. Meier is the former Chief Operating Officer and Chief Financial Officer of Advanced Medical Optics. From April 2006 to February 2007, he was Advanced Medical Optics' Executive Vice President, of Operations and Chief Financial Officer, and from April 2002 to February 2004, Mr. Meier was Corporate Vice President and Chief Financial Officer. Prior to joining Advanced Medical Optics, Mr. Meier was the Executive Vice President and Chief Financial Officer of Valeant Pharmaceuticals, Inc., from January 2000, and Senior Vice President & Treasurer from May 1998 to January 2000. Before joining Valeant, Mr. Meier was an executive with the investment banking firm of Schroder & Co. Inc. in New York, from 1996. Prior to Mr. Meier's experience at Schroder & Co., he held various financial and banking positions at Soloman Smith Barney, Manufacturers Hanover Corporation, Australian Capital Equity, and Greyhound Lines, Inc.